Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
128 hedge funds and large institutions have $574M invested in Merrimack Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 31 reducing their positions, and 27 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 31
23% more capital invested
Capital invested by funds: $467M → $574M (+$107M)
9% less funds holding
Funds holding: 140 → 128 (-12)
29% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $2.15M
44% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$31.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.97M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.61M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.27M |
| 2 |
Renaissance Technologies
New York
|
-$4.01M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.27M |
| 4 |
LIM
Lagoda Investment Management
New York
|
-$1.97M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.39M |
MACK Hedge Fund Activity: Q3 2016 in Review
128 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2016, worth a combined $574M — up 23% from $467M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MACK and 15 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 47 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $31.4M. The largest seller was Vanguard Group, cutting an estimated $6.27M.
- 128 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2016, down from 140 in Q2 2016.
- Funds reported $574M of Merrimack Pharmaceuticals, Inc. stock for Q3 2016, up 23% quarter-over-quarter.
- 15 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2016 and 27 closed out, a net change of -12 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2016 was Consonance Capital Management, an estimated $31.4M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2016 was Vanguard Group, an estimated $6.27M sold.
Based on aggregated 13F filings for Q3 2016.